首页> 外文期刊>Immunogenetics >Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21
【24h】

Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21

机译:HLA I类改变表型在大肠癌中的分布:HLA单倍型缺失的高频率与6p21染色体区域杂合性的丧失相关

获取原文
获取原文并翻译 | 示例
           

摘要

HLA class I loss or down-regulation is a widespread mechanism used by tumor cells to avoid tumor recognition by cytotoxic T lymphocytes, and thus favor tumor immune escape. Multiple mechanisms are responsible for these HLA class I alterations. In different epithelial tumors, loss of heterozygosity (LOH) at chromosome region 6p21.3, leading to HLA haplotype loss, occurs in 6–50% of all cases depending on the tumor entity. In this paper we report the frequency of LOH at 6p21 in 95 colorectal carcinomas (CRC) previously analyzed for altered HLA class I expression with immunohistological techniques. We used PCR microsatellite amplification of selected STR markers located on Chromosome 6 to identify LOH with DNA from microdissected tumor tissues and the surrounding stroma. Sequence-specific oligonucleotide analysis was performed in microdissected stroma and tumor cells for HLA typing, and to detect HLA haplotype loss. A high frequency (40%) of HLA haplotype loss was found in CRC. Eight tumors showed microsatellite instability. We sometimes observed two or more mechanisms responsible for HLA alteration within the same HLA-altered phenotype, such as LOH and HLA class I total loss. In 25 tumors (26%) no HLA class I alteration could be identified. These data are potentially relevant for CRC patients undergoing T-cell-based immunotherapy.
机译:HLA I类丢失或下调是肿瘤细胞广泛使用的机制,可避免细胞毒性T淋巴细胞识别肿瘤,从而促进肿瘤免疫逃逸。多种机制负责这些HLA I类更改。在不同的上皮肿瘤中,在6p21.3染色体区域的杂合性(LOH)丢失,导致HLA单倍型丢失,在所有病例中有6-50%取决于肿瘤的实体。在本文中,我们报告了95例大肠癌(CRC)在6p21处LOH的频率,该频率先前已通过免疫组织学技术分析了改变的HLA I类表达。我们使用位于6号染色体上的选定STR标记的PCR微卫星扩增来鉴定LOH与来自显微解剖的肿瘤组织和周围基质的DNA。在显微解剖的基质和肿瘤细胞中进行序列特异性寡核苷酸分析以进行HLA分型,并检测HLA单倍型缺失。在CRC中发现高频率(40%)的HLA单倍型缺失。八个肿瘤显示微卫星不稳定。有时,我们观察到在同一HLA改变的表型内导致HLA改变的两种或多种机制,例如LOH和HLA I类总损失。在25个肿瘤(26%)中,未发现HLA I类改变。这些数据可能与正在接受基于T细胞免疫疗法的CRC患者相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号